DMRADamora Therapeutics, Inc.同业对比
Damora Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMRA本股 | $1.3B#6 | 2.7x#2 | 2.5x#4 | — | — | -878.8%#12 | — | -40.7%#10 | — | — | 183.2%#1 | — |
| ANAB | $1.4B#1 | 8.6x#3 | 135.4x#12 | 6.1x#3 | 157.0%#2 | 90.9%#2 | 96.7%#1 | -125.0%#11 | — | — | 31.0%#6 | — |
| ETON | $1.4B#2 | — | 30.6x#11 | 17.8x#5 | 104.9%#3 | -20.4%#6 | -1.1%#3 | -9.9%#5 | -1.8%#2 | 4#2 | 176.2%#2 | — |
| MLYS | $1.4B#3 | — | 2.6x#6 | — | — | 13.0%#4 | — | -28.1%#8 | -41.3%#5 | — | -60.5%#9 | — |
| KARD | $1.3B#4 | — | 2.2x#3 | — | — | — | — | 0.0%#2 | — | — | — | — |
| OMER | $1.3B#5 | 10.5x#4 | — | 17.9x#6 | -34.0%#6 | 97.9%#1 | -166.4%#6 | — | -151.8%#7 | — | 149.0%#3 | — |
| NKTR | $1.3B#7 | — | 1.4x#2 | 23.3x#7 | -43.9%#7 | -37.8%#7 | -253.7%#7 | -18.2%#6 | -14.0%#4 | — | -42.0%#8 | — |
| OPK | $1.3B#8 | — | 1.1x#1 | 2.1x#2 | -14.9%#5 | -324.0%#11 | -19.3%#4 | -19058.1%#12 | -13.3%#3 | 4#2 | — | — |
| LBRX | $1.3B#9 | 1.7x#1 | 3.8x#10 | — | — | 60.1%#3 | — | -7.6%#4 | — | — | 140.8%#4 | — |
| TYRA | $1.2B#10 | — | 3.5x#9 | — | — | -38.7%#9 | — | -33.9%#9 | — | — | 31.6%#5 | — |
| RAPP | $1.2B#11 | — | 2.8x#7 | — | — | -42.4%#10 | — | -26.4%#7 | — | — | -14.4%#7 | — |
| SNDX | $1.2B#12 | — | — | 6.8x#4 | 627.8%#1 | 10.5%#5 | -158.4%#5 | — | -143.0%#6 | — | — | — |
| AMPH | $1.1B#13 | 15.9x#5 | 2.6x#5 | 1.6x#1 | -1.7%#4 | -38.5%#8 | 19.5%#2 | 22.0%#1 | 13.2%#1 | 5#1 | — | — |
| AVLN | $1.1B#14 | — | 2.8x#8 | — | — | — | — | 0.0%#2 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议